F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Slides:

Advertisements

Similar presentations

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Advertisements

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc

Tuomo Puhakka, MDa, Mika J

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome Paul Steinberg, MDa, Bruce E.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Ulrich Wahn, MDa. ‡, Eli O. Meltzer, MDb. ‡, Albert F. Finn, MDc

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis William R. Lumry, MD Journal of.

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children Mark Boguniewicz, MDa, Virginia C. Fiedler,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma Patrick Booms, MSca, David.

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Badrul A. Chowdhury, MD, PhD

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Edwin A. Bronsky, MD, Howard Druce, MD, Steven R. Findlay, MD, Frank C

Adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors associated with elevated serum IgE and eosinophilia Carol K. Fosso, MDa,

Product characteristics and pharmacokinetics of intranasal ipratropium bromide Chester C. Wood, MDa, Philip Fireman, MDb, Jay Grossman, MDc, Margaret.

Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

Elinor Simons, MDa, William M

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial William Busse, MDa,

Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol Henry Milgrom, MDa, David P. Skoner,

Conjunctivitis medicamentosa

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma Gail.

Practice Notes from the AAAAI

Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic.

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model John M.

A review of the current guidelines for allergic rhinitis and asthma

Physician-targeted program on inhaled therapy for childhood asthma

Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: Effects of single allergen challenge Adriaan.

News & Notes Journal of Allergy and Clinical Immunology

Correlation between alcohol-induced asthma and acetaldehyde dehydrogenase-2 genotype Atsuko Takao, MDa, Terufumi Shimoda, MDa, Shigeru Kohno, MDa, Sadahiro.

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Thomas B. Casale, MDa, I. Leonard Bernstein, MDb, William W

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma Gordon D. Raphael, MDa, Robert.

News & Notes Journal of Allergy and Clinical Immunology

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic.

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

The 30th anniversary of the American Board of Allergy and Immunology: Then and now Lynn Des Prez a, Charles E. Reed, MD, Lawrence B. Schwartz, MDb, John.

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

The role and remediation of animal allergens in allergic diseases

Practice Notes from the AAAI

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Anaphylaxis after initial ingestion of rambutan, a tropical fruit

Terence J. Furlong, MSa, Jennifer DeSimonea, Scott H. Sicherer, MDb

Tuomo Puhakka, MDa, Mika J

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Larry C. Borish, MDa, Harold S

Quantification of conjunctival vascular reaction by digital imaging

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa,

News & Notes Journal of Allergy and Clinical Immunology

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal.

Desloratadine: A new, nonsedating, oral antihistamine

Presentation transcript:

Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc Journal of Allergy and Clinical Immunology Volume 111, Issue 3, Pages 617-622 (March 2003) DOI: 10.1067/mai.2003.168 Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 1 Mean percentage reduction in the 4-week average morning-evening instantaneous TSSs. Baseline values were 10.7 and 10.6 for the desloratadine- and placebo-treated groups, respectively. Journal of Allergy and Clinical Immunology 2003 111, 617-622DOI: (10.1067/mai.2003.168) Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 2 Mean percentage reduction in the 4-week average morning-evening reflective total nasal symptom scores. Baseline value was 7.0 in both the desloratadine- and placebo-treated groups. Journal of Allergy and Clinical Immunology 2003 111, 617-622DOI: (10.1067/mai.2003.168) Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 3 Mean percentage reduction in morning-evening instantaneous individual nasal symptom scores over days 1 through 29. Baseline values in both the desloratadine- and placebo-treated groups were as follows: rhinorrhea, 1.8; nasal itching, 1.6; postnasal drip/drainage, 1.8; itching/burning eyes, 1.5; tearing/watering eyes, 1.3; and itching of ears or palate, 1.3. For sneezing, the baseline values were 1.4 in the desloratadine-treated group and 1.5 in the placebo-treated group. Journal of Allergy and Clinical Immunology 2003 111, 617-622DOI: (10.1067/mai.2003.168) Copyright © 2003 Mosby, Inc. Terms and Conditions